Navigation Links
Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site
Date:2/12/2008

the Transitions brand, expand the depth of consumer outreach and education about the importance that healthy sight has on overall health and wellness," said Brett Craig, president, Transitions Optical. "We are proud to offer the most advanced photochromic technology to today's conscientious consumers and provide the ideal, everyday lens choice to enhance visual quality and eye health protection today and tomorrow," added Craig.

To coincide with the new advertising campaign, Transitions Optical will launch an enhanced web site that will allow consumers and industry professionals to:

* Experience Transitions - interactive component will allow for consumers

to visually experience the benefit of Transitions lenses through a

simulation.

* Get Your Local UV Forecast - consumers will be able to obtain their

city's UV forecast on any given day.

* Find an ECP - find a local eyecare professional, schedule an

examination and learn about how Transitions lenses can benefit you.

* Take an Online Personal Eye Quiz - find out more about what frame and

lens options best suit your lifestyle and needs.

As part of its digital brand expansion and to encourage consumers to share information and inspire action in support of healthy sight, Transitions has established a presence on leading social networking sites including YouTube and Facebook.

About Transitions Optical, Inc.

Transitions Optical is a joint venture of PPG Industries, Inc. and Essilor International. The first to successfully commercialize a plastic photochromic lens in 1990, today the company is a leading supplier of photochromics to optical manufacturers worldwide. Transitions Optical offers the most advanced photochromic technology and the widest selection of lens designs, materials and brand names.

Transitions(R) lenses are as clear as regular eyeglass lenses until dangerous UV rays are present. Then, the
'/>"/>

SOURCE Transitions Optical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Optical scientist honored for understanding and improving vision
2. Minority patients prefer optical colonoscopy for colorectal cancer screening
3. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
4. Shamir Optical Industry Ltd. to Host Conference Call Announcing Third Quarter 2007 Earnings Results
5. Optical Coherence Tomography Market to Top $800 Million by 2012
6. S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President
7. MassMutual Promotes Debra Palermino to Senior Vice President of Human Resources
8. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
9. Vitasoy Promotes the Soy Breast Health Connection
10. AvMed Promotes Kirk Cianciolo to Senior Vice President and Chief Medical Officer
11. Lifespring Health Promotes Health and Fitness by Sponsoring Silicon Valley Marathon on November 3rd and 4th
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Virtual maps for the blind 56801 1Virtual maps for the blind 56801 2Virtual maps for the blind 56801 3Changing the course of nature 3A Are fisheries directing the evolution of fish populations 3F 9874 1Changing the course of nature 3A Are fisheries directing the evolution of fish populations 3F 9874 2Stevens to host 2009 N J Inventors Hall of Fame Dinner 9871 1Stevens to host 2009 N J Inventors Hall of Fame Dinner 9871 2